Browsing Tag
Verastem Oncology
2 posts
Verastem Oncology’s avutometinib plus defactinib trial in LGSOC published in JCO with robust clinical responses
Verastem Oncology published pivotal Phase 2 RAMP 201 trial results in JCO, showing strong response rates for avutometinib plus defactinib in recurrent LGSOC.
Verastem gets FDA orphan drug status for COPIKTRA for T-Cell lymphoma
Verastem Oncology has secured orphan drug designation for COPIKTRA (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), from…